


What is claimed is:

1. A compound of formula (V) or a pharmaceutically acceptable salt thereof,




(V)

wherein,

the carbon atom marked with a "*" is a chiral carbon atom, which is in the form of a single (*R*)-enantiomer or a single (*S*)-enantiomer, or enriched in one enantiomer;

R_1 is OH, CN, NH_2 , F_3C-O- or selected from the group consisting of propyl, butyl, pentyl,



alkenyl, C_{2-5} heteroalkenyl, C_{3-6} cycloalkyl and 3-6 membered heterocycloalkyl, each of the group is optionally substituted by 1, 2 or 3 R ;

R_2 is H, OH, CN, NH_2 , halogen, or selected from the group consisting of C_{1-3} alkyl, C_{1-3} heteroalkyl, C_{3-6} cycloalkyl and 3-6 membered heterocycloalkyl, each of the group is optionally substituted by 1, 2 or 3 R ;

R_3 is selected from the group consisting of C_{1-6} alkyl and C_{3-6} cycloalkyl, each of the group is optionally substituted by 1, 2 or 3 R ;

m is 1, 2, 3, 4 or 5;



R is H, halogen, OH, CN, NH_2 , or selected from the group consisting of C_{1-3} alkyl and C_{1-3} heteroalkyl, each of the group is optionally substituted by 1, 2 or 3 R' ;






R' is selected from the group consisting of F, Cl, Br, I, OH, CN, NH_2 , CH_3 , CH_3CH_2 , CH_3O , CF_3 , CHF_2 and CH_2F ;



the "hetero" refers to heteroatom or heteroatomic group; the "hetero" in the C_{2-5} heteroalkenyl, 3-6 membered heterocycloalkyl, C_{1-3} heteroalkyl is independently selected from the group consisting of N, -O-, -S-, =O, =S, -C(=O)O-, -C(=O)-, -C(=S)-, -S(=O)- and -S(=O)₂-;









in any of the above cases, the number of the heteroatom or the heteroatomic group is independently 1, 2 or 3.



2. The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein, R is H, F, Cl, Br, I, OH, CN, NH₂, CH₃, CH₃CH₂, CH₃O, CF₃, CHF₂ or CH₂F.









3. The compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein, R₁ is OH, CN, NH₂, , or selected from the group consisting of propyl, , ,

, , , , , , C₂₋₃ alkenyl, C₂₋₃ heteroalkenyl, C₃₋₆ cycloalkyl and 3-6 membered heterocycloalkyl, each of the group is optionally substituted by 1, 2 or 3 R.

4. The compound or the pharmaceutically acceptable salt thereof according to claim 3, wherein, R₁ is OH, CN, NH₂, , or selected from the group consisting of , ,

, , , , , , , , , , and , each of the group is optionally substituted by 1, 2 or 3 R.

5. The compound or the pharmaceutically acceptable salt thereof according to claim 4, wherein, R₁ is selected from the group consisting of OH, CN, NH₂, , , ,

, , , , , , , , , , and .

6. The compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein, R₂ is H, OH, CN, NH₂, halogen, or selected from the group consisting of C₁₋₃ alkyl, C₁₋₃ heteroalkyl and C₃₋₆ cycloalkyl, each of the group is optionally substituted by 1, 2 or 3 R.

7. The compound or the pharmaceutically acceptable salt thereof according to claim 6, wherein, R₂ is H, OH, CN, NH₂, F, Cl, Br, I, or selected from the group consisting of CH₃, , , , and , each of the group is optionally substituted by 1, 2 or 3 R.

8. The compound or the pharmaceutically acceptable salt thereof according to claim 7, wherein, R₂

9. The compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein, R₃ is selected from the group consisting of C₁₋₄ alkyl and C₃₋₆ cycloalkyl, each of the group is optionally substituted by 1, 2 or 3 R.

R₃ is selected from the group consisting of , , ,  and 


12. The compound or the pharmaceutically acceptable salt thereof according to claim 11, wherein,

13. The compound or the pharmaceutically acceptable salt thereof according to any one of claims 1-12, wherein, the carbon atom with a "*" is a chiral carbon atom, which is in the form of a single (*R*)-enantiomer or enriched in one enantiomer.

(II)

(III)

and



wherein,

the carbon atom marked with a "*" is a chiral carbon atom, which is in the form of a single (*R*)-enantiomer or (*S*)-enantiomer, or enriched in one enantiomer;

R₄ is H, or selected from the group consisting of ethyl, *n*-propyl, isopropyl and C₁₋₃ heteroalkyl, each of the group is optionally substituted by 1, 2 or 3 R;

X is selected from the group consisting of CH and N;

Y is selected from the group consisting of O and CH₂;

each of L₁ and L₂ is independently selected from the group consisting of a single bond, -(CH₂)_n- and -C(=O)-;

with the provision that L₁ and L₂ are not both a single bond;


n is 1 or 2;


m, R, R₂, R₃ and the "hetero" in C₁₋₃ heteroalkyl are as defined in any one of claims 1-11;


the number of the heteroatom or the heteroatomic group is independently 1 or 2.

15. The compound or the pharmaceutically acceptable salt thereof according to claim 14, wherein, the carbon atom marked with a "*" is a chiral carbon atom, which is in the form of a single (*R*)-enantiomer or enriched in one enantiomer.


16. A compound or a pharmaceutically acceptable salt thereof, wherein, the compound is selected from the group consisting of









,




,




,




,




,




,




,




,




,












,





and



17. The compound or the pharmaceutically acceptable salt thereof according to claims 16, wherein, the compound is selected from the group consisting of







18. A pharmaceutical composition comprising a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1-17, and a pharmaceutically acceptable carrier.

19. A use of the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1-17 or the pharmaceutical composition according to claim 18 in manufacturing a medicament for treating hepatitis B.